Related Experiment Video
Updated: Apr 21, 2026
08:04
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
18.6K
mTOR pathway: A current, up-to-date mini-review (Review)
Paul Zarogoulidis1, Sofia Lampaki1, J Francis Turner2
1Pulmonary Department-Oncology Unit, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece.
Oncology Letters
|November 1, 2014
Summary
The mammalian target of rapamycin (mTOR) pathway is linked to lung cancer development. Inhibiting this pathway shows promise as a potential lung cancer treatment.
Area of Science:
- Molecular Biology
- Oncology
Background:
- Mammalian target of rapamycin (mTOR) is a key kinase regulating cell growth, proliferation, survival, and protein synthesis.
- The mTOR pathway is implicated in various cellular processes, including responses to hormones, growth factors, and nutrients.
Purpose of the Study:
- To explore the association between the mTOR pathway and lung carcinogenesis.
- To review clinical trials investigating mTOR inhibitors for lung cancer treatment.
Main Methods:
- Literature review of preclinical and clinical studies on mTOR and lung cancer.
- Analysis of the role of mTOR in lung cancer development and progression.
Main Results:
- Preclinical studies suggest that antagonizing the mTOR pathway has an antitumor effect on lung cancer.
- Early clinical trials indicate that mTOR inhibitors may be effective against lung carcinoma.
Conclusions:
- The mTOR pathway is a significant factor in lung carcinogenesis.
- mTOR inhibitors represent a potential therapeutic strategy for lung cancer.
